These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35653194)

  • 1. Immune landscape of a genetically engineered murine model of glioma compared with human glioma.
    Zamler DB; Shingu T; Kahn LM; Huntoon K; Kassab C; Ott M; Tomczak K; Liu J; Li Y; Lai I; Zorilla-Veloz R; Yee C; Rai K; Kim BY; Watowich SS; Heimberger AB; Draetta GF; Hu J
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35653194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
    Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF
    Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma.
    Rajendran S; Hu Y; Canella A; Peterson C; Gross A; Cam M; Nazzaro M; Haffey A; Serin-Harmanci A; Distefano R; Nigita G; Wang W; Kreatsoulas D; Li Z; Sepeda JA; Sas A; Hester ME; Miller KE; Elemento O; Roberts RD; Holland EC; Rao G; Mardis ER; Rajappa P
    Cell Rep; 2023 Mar; 42(3):112197. PubMed ID: 36871221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.
    Szulzewsky F; Pelz A; Feng X; Synowitz M; Markovic D; Langmann T; Holtman IR; Wang X; Eggen BJ; Boddeke HW; Hambardzumyan D; Wolf SA; Kettenmann H
    PLoS One; 2015; 10(2):e0116644. PubMed ID: 25658639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse Macrophages Constituted the Glioma Microenvironment and Influenced by PTEN Status.
    Zhou F; Shi Q; Fan X; Yu R; Wu Z; Wang B; Tian W; Yu T; Pan M; You Y; Wang Y
    Front Immunol; 2022; 13():841404. PubMed ID: 35265085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
    Yeo AT; Rawal S; Delcuze B; Christofides A; Atayde A; Strauss L; Balaj L; Rogers VA; Uhlmann EJ; Varma H; Carter BS; Boussiotis VA; Charest A
    Nat Immunol; 2022 Jun; 23(6):971-984. PubMed ID: 35624211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
    Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
    Front Immunol; 2022; 13():993444. PubMed ID: 36685592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune microenvironment of gliomas.
    Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
    Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.
    Moncayo G; Grzmil M; Smirnova T; Zmarz P; Huber RM; Hynx D; Kohler H; Wang Y; Hotz HR; Hynes NE; Keller G; Frank S; Merlo A; Hemmings BA
    Neuro Oncol; 2018 Apr; 20(5):621-631. PubMed ID: 29401256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune suppression in gliomas.
    Grabowski MM; Sankey EW; Ryan KJ; Chongsathidkiet P; Lorrey SJ; Wilkinson DS; Fecci PE
    J Neurooncol; 2021 Jan; 151(1):3-12. PubMed ID: 32542437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.
    Kong LY; Wu AS; Doucette T; Wei J; Priebe W; Fuller GN; Qiao W; Sawaya R; Rao G; Heimberger AB
    Clin Cancer Res; 2010 Dec; 16(23):5722-33. PubMed ID: 20921210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F11R is a novel monocyte prognostic biomarker for malignant glioma.
    Pong WW; Walker J; Wylie T; Magrini V; Luo J; Emnett RJ; Choi J; Cooper ML; Griffith M; Griffith OL; Rubin JB; Fuller GN; Piwnica-Worms D; Feng X; Hambardzumyan D; DiPersio JF; Mardis ER; Gutmann DH
    PLoS One; 2013; 8(10):e77571. PubMed ID: 24147027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas.
    Kanvinde PP; Malla AP; Connolly NP; Szulzewsky F; Anastasiadis P; Ames HM; Kim AJ; Winkles JA; Holland EC; Woodworth GF
    Glia; 2021 Sep; 69(9):2059-2076. PubMed ID: 33638562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.
    Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B
    Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
    Lin GL; Nagaraja S; Filbin MG; SuvĂ  ML; Vogel H; Monje M
    Acta Neuropathol Commun; 2018 Jun; 6(1):51. PubMed ID: 29954445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Myeloid Cells in GBM Immunosuppression.
    Lin YJ; Wu CY; Wu JY; Lim M
    Front Immunol; 2022; 13():887781. PubMed ID: 35711434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specialized functions and sexual dimorphism explain the functional diversity of the myeloid populations during glioma progression.
    Ochocka N; Segit P; Wojnicki K; Cyranowski S; Swatler J; Jacek K; Grajkowska W; Kaminska B
    Cell Rep; 2023 Jan; 42(1):111971. PubMed ID: 36640350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.